Pelthos Therapeutics Files Amended Financials Post-Merger

TL;DR

Pelthos Therapeutics amended its filing with LNHC financials and pro forma data post-merger.

AI Summary

Pelthos Therapeutics Inc. filed an 8-K/A on September 16, 2025, to amend a previous filing. This amendment includes unaudited condensed financial statements for LNHC as of June 30, 2025 and 2024, and for the three and six-month periods ended June 30, 2025 and 2024. It also provides the required pro forma financial information in connection with a Merger.

Why It Matters

This filing provides updated financial information related to a merger, offering investors a clearer picture of the combined entity's financial health and performance.

Risk Assessment

Risk Level: medium — The filing involves amended financial statements and pro forma information related to a merger, which can introduce complexities and potential uncertainties.

Key Players & Entities

• Pelthos Therapeutics Inc. (company) — Filer of the 8-K/A
• LNHC (company) — Company whose financial statements are included
• June 30, 2025 (date) — Reporting period end date for financial statements
• June 30, 2024 (date) — Reporting period end date for financial statements
• September 16, 2025 (date) — Filing date of the 8-K/A

FAQ

From the Filing

0001753926-25-001500.txt : 20250916 0001753926-25-001500.hdr.sgml : 20250916 20250916161055 ACCESSION NUMBER: 0001753926-25-001500 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20250916 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250916 DATE AS OF CHANGE: 20250916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251317440 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K/A 1 g084946_8-ka.htm 8-K/A true The Company is filing this Current Report on Form 8-K/A to amend the Original Filing to provide unaudited condensed financial statements of LNHC as of June 30, 2025 and 2024 and for the three and six months ended June 30, 2025 and June 30, 2024 and the pro forma financial information required by Item 9.01(b) of Form 8-K in connection with the Merger. 0001919246 0001919246 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K/A (Amendment No. 1)   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 16, 2025 (July 1, 2025)   Pelthos Therapeutics Inc.   (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400   (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period